Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor

被引:40
|
作者
Chen, Quan [1 ]
Miller, Laurence J. [1 ]
Dong, Maoqing [1 ]
机构
[1] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2010年 / 299卷 / 01期
关键词
G protein-coupled receptor; ligand binding; receptor biological activity; receptor cell surface expression; CELL-SURFACE EXPRESSION; PROTEIN-COUPLED RECEPTORS; SECRETIN RECEPTOR; LIGAND-BINDING; AT(1) RECEPTOR; OLIGOSACCHARIDES; ACTIVATION; DOMAIN; SITES;
D O I
10.1152/ajpendo.00067.2010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chen Q, Miller LJ, Dong M. Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor. Am J Physiol Endocrinol Metab 299: E62-E68, 2010. First published April 20, 2010; doi:10.1152/ajpendo.00067.2010.-The family B G protein-coupled glucagon-like peptide 1 (GLP-1) receptor is an important drug target for treatment of type 2 diabetes. Like other family members, the GLP-1 receptor is a glycosylated membrane protein that contains three potential sites for N-linked glycosylation within the functionally important extracellular amino-terminal domain. However, the roles for each potential site of glycosylation in receptor biosynthesis, trafficking, and function are not known. In this work, we demonstrated that tunicamycin inhibition of glycosylation of the GLP-1 receptor expressed in CHO cells interfered with biosynthesis and intracellular trafficking, thereby eliminating natural ligand binding. To further investigate the roles of each of the glycosylation sites, site-directed mutagenesis was performed to eliminate these sites individually and in aggregate. Our results showed that mutation of each of the glycosylation sites individually did not interfere with receptor expression on the cell surface, ligand binding, and biological activity. However, simultaneous mutation of two or three glycosylation sites resulted in almost complete loss of GLP-1 binding and severely impaired biological activity. Immunostaining studies demonstrated receptor biosynthesis but aberrant trafficking, with most of the receptor trapped in the endoplasmic reticulum and golgi compartments and little of the receptor expressed on the cell surface. Interestingly, surface expression, ligand binding, and biological activity of these mutants improved significantly when biosynthesis was slowed using low temperature (30 degrees C). These data suggest that N-linked glycosylation of the GLP-1 receptor is important for its normal folding and trafficking to the cell surface.
引用
收藏
页码:E62 / E68
页数:7
相关论文
共 50 条
  • [21] Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking
    Lucey, Maria
    Ashik, Tanyel
    Marzook, Amaara
    Wang, Yifan
    Goulding, Joelle
    Oishi, Atsuro
    Broichhagen, Johannes
    Hodson, David J.
    Minnion, James
    Elani, Yuval
    Jockers, Ralf
    Briddon, Stephen J.
    Bloom, Stephen R.
    Tomas, Alejandra
    Jones, Ben
    MOLECULAR PHARMACOLOGY, 2021, 100 (04) : 319 - 334
  • [22] Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism
    Lei, Saifei
    Clydesdale, Lachlan
    Dai, Antao
    Cai, Xiaoqing
    Feng, Yang
    Yang, Dehua
    Liang, Yi-Lynn
    Koole, Cassandra
    Zhao, Peishen
    Coudrat, Thomas
    Christopoulos, Arthur
    Wang, Ming-Wei
    Wootten, Denise
    Sexton, Patrick M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (24) : 9370 - 9387
  • [23] Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R) Has a Critical Role in GLP-1 Peptide Binding and Receptor Activation
    Koole, Cassandra
    Wootten, Denise
    Simms, John
    Miller, Laurence J.
    Christopoulos, Arthur
    Sexton, Patrick M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (06) : 3642 - 3658
  • [24] Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
    Zheng, Zhikai
    Zong, Yao
    Ma, Yiyang
    Tian, Yucheng
    Pang, Yidan
    Zhang, Changqing
    Gao, Junjie
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [25] Glucagon-like peptide-1 receptor agonists in neoplastic diseases
    Ji, Lisan
    He, Xianzhen
    Min, Xinwen
    Yang, Handong
    Wu, Wenwen
    Xu, Hao
    Chen, Jun
    Mei, Aihua
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [26] Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
    Willard, Francis S.
    Sloop, Kyle W.
    EXPERIMENTAL DIABETES RESEARCH, 2012,
  • [27] A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness
    Beinborn, M
    Worrall, CI
    McBride, EW
    Kopin, AS
    REGULATORY PEPTIDES, 2005, 130 (1-2) : 1 - 6
  • [28] Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer
    Cases, Ana Ines
    Ohtsuka, Takao
    Kimura, Hidey
    Zheng, Biao
    Shindo, Koji
    Oda, Yoshinao
    Mizumoto, Kazuhiro
    Nakamura, Masafumi
    Tanaka, Masao
    ONCOLOGY REPORTS, 2015, 34 (04) : 1717 - 1725
  • [29] Small-molecule agonists for the glucagon-like peptide 1 receptor
    Knudsen, Lotte Bjerre
    Kiel, Dan
    Teng, Min
    Behrens, Carsten
    Bhumralkar, Dilip
    Kodra, Janos T.
    Holst, Jens J.
    Jeppesen, Claus B.
    Johnson, Michael D.
    de Jong, Johannes Cornelis
    Jorgensen, Anker Steen
    Kercher, Tim
    Kostrowicki, Jarek
    Madsen, Peter
    Olesen, Preben H.
    Petersen, Jacob S.
    Poulsen, Fritz
    Sidelmann, Ulla G.
    Sturis, Jeppe
    Truesdale, Larry
    May, John
    Lau, Jesper
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (03) : 937 - 942
  • [30] The complexity of signalling mediated by the glucagon-like peptide-1 receptor
    Fletcher, Madeleine M.
    Halls, Michelle L.
    Christopoulos, Arthur
    Sexton, Patrick M.
    Wootten, Denise
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2016, 44 : 582 - 588